In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...

incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 38,541.57 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ...

UK pharma major GSK has into an agreement with Chongqing Zhifei Biological Products (Zhifei) to revize the terms on which ...

GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034.

The annual per capita pharmaceutical sales are less than US$32. Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...

Nine months out from landing $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has ...

GSK respiratory/immunology research and development global head Kaivan Khavandi stated: “Working with Relation enables us to ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.